Mayo Clinic Researcher to Present Preclinical Findings on ADI-100 Immune Therapy

Aditxt Inc. will convene a scientific presentation featuring Dr. Charles Howe from Mayo Clinic to discuss critical findings from a preclinical study of ADI-100, the lead therapeutic candidate developed by the company's subsidiary, Adimune Inc.

The May 2, 2025 update will provide researchers and medical professionals insight into potential advancements in immune modulation therapy. Dr. Howe will be joined by Aditxt's Chief Innovation Officer, Dr. Shahrokh Shabahang, and Adimune's Co-CEO, Dr. Friedrich Kapp, to present the latest research developments.

This presentation represents a significant opportunity to explore innovative approaches to immune system treatment. Immune modulation therapies hold substantial promise for addressing complex medical conditions by potentially regulating immune system responses more precisely than traditional treatment methods.

Aditxt's strategic approach involves collaborating with research institutions and industry partners to accelerate health innovations. The company's platform is designed to support interdisciplinary research and development, with a focus on addressing critical societal health challenges.

The upcoming presentation underscores Aditxt's commitment to developing novel therapeutic strategies. By leveraging expertise from renowned institutions like Mayo Clinic and fostering collaborative research environments, the company aims to advance medical understanding and potential treatment options for immune-related disorders.

The preclinical study of ADI-100 represents an important step in evaluating the therapeutic potential of new immune modulation approaches. Researchers and medical professionals will be closely monitoring the findings to assess the candidate's potential clinical applications and implications for future treatment strategies.